ST. PAUL, Minn. (AP) — Minnesota’s share of a $71 million multistate settlement with biotech drugmaker Amgen tops $1.2 million.

The deal to end an investigation into illegal marketing of two drugs made by the company was announced earlier this week. Court papers filed in Minnesota say the state’s portion will go toward individuals who experienced harm, administrative costs and the general treasury if any is left.

READ MORE: Hopkins Police Investigating Homicide At Apartment Building

Forty-eight states and Washington D.C. reached the agreement with Amgen, the maker of drugs to treat anemia in cancer patients and ailments like plaque psoriasis.

READ MORE: Mass Casualty Simulation Helps Nat'l Guard, Children's Minnesota Practice Treating Kids

The company says the settlement isn’t an admission of guilt or wrongdoing.

MORE NEWS: Amid Missionary Hostage Crisis, Minnesotan From Port-Au-Prince Wishes 'Haiti Would Get The Help They Need'

(© Copyright 2015 The Associated Press. All Rights Reserved. This material may not be published, broadcast, rewritten or redistributed.)